JP4810129B2 - Non-aqueous emulsion composition - Google Patents

Description

The present invention is a non-aqueous emulsion having a microemulsion structure having a small amount of oil as a skin external preparation or skin cosmetic, improving the moisture retention performance and temperature stability of the base, and having excellent drug stability, compounding properties, release characteristics and usability It relates to a mold composition.

Conventionally, to improve drug stability in an oil-in-water emulsion composition, the base is adjusted to the optimum pH of the drug in order to prevent the degradation mechanism (oxidation reaction and / or hydrolysis reaction) of the drug to be added. Or prescribe antioxidants and chelating agents. If there is a problem with the stability of the drug, it is necessary to remove dissolved oxygen in the manufacturing process, or to consider the packaging design, that is, the selection of an airtight container, light shielding by titanium oxide, storage temperature, etc. . Therefore, at present, various preparations have been made for designing an oil-in-water emulsion composition with good usability.

In recent years, research on emulsification has advanced greatly, many emulsifiers have been developed, and emulsification techniques have also been improved. However, in order to obtain a stable emulsion, in general, a plurality and a large amount of a surfactant are required. Therefore, in order to use this as a skin external preparation or a skin cosmetic, the feeling of use and stability are actually used. There were problems such as lowering.

There is a non-aqueous emulsification method as a method for obtaining a stable emulsion while reducing the amount of surfactant used. In this method, a hydrophilic nonionic surfactant is added to a water-soluble solvent, and oil is added to the non-emulsification method. Oil-in-water emulsified composition with excellent emulsification stability and stable emulsification over a long period of time by adding water after adding a phase to prepare an oil-in-water emulsifier in a water-soluble solvent (See Patent Document 1). However, no mention is made of a preparation containing a drug, and no mention is made of whether moisturizing the base contributes to the promotion of percutaneous absorption of the drug in the base. Furthermore, it describes that glycerin is not suitable as a water-soluble solvent because of its poor solubility with hydrophilic nonionic surfactants (see Non-Patent Document 1).

In addition, a pre-emulsion prepared by adding water to a non-aqueous emulsion composition composed of a polyglycerin fatty acid ester, an oil component and a polyhydric alcohol contains an emulsion in which emulsified particles are refined to 1 μm or less under high pressure and a humectant. The composition which becomes is proposed (refer patent document 2). The composition according to the present invention is excellent in moisturizing effect, feeling of use, storage stability and skin safety. However, in order to prepare an emulsion under high pressure, special equipment and its equipment investment are required. It becomes. Moreover, in patent document 2, nothing is mentioned about the formulation which mix | blended the chemical | medical agent.

By using polyglycerol fatty acid ester and alkanoyl lactic acid in combination, an oil-in-water emulsion composition is proposed that is excellent in emulsion stability even if it contains an electrolyte as a component, and that the emulsion state is stably maintained over a long period of time. However, this method is excellent for hydrophilic drugs (electrolytes) such as nucleic acid-related substances, but does not suggest lipophilic drugs.

Furthermore, the moisturizing effect of glycerin is widely known and widely used in ordinary liquids and semi-solid preparations (creams, lotions). Physiological effects of the moisturizing effect caused by glycerin, i.e., the relationship between the swelling of the stratum corneum due to hydration and the ability of the drug to move into the skin, have not been clarified physiologically.
JP-A-51-55783 JP 2000-86435 A JP 2002-234830 A Fragrance Journal, 7, 25-35 (1993) "Development of external preparations for skin from the viewpoint of cosmetic manufacturers"

The present invention provides a microemulsion structure that has high moisturizing performance and temperature stability of a base produced using a small amount of a hydrophilic nonionic surfactant, and is excellent in drug stability, compounding properties, release characteristics and usability. It aims at providing the non-aqueous emulsion type composition which has.

The present inventors further studied the non-aqueous emulsification method, and a method (condition) of adding glycerin in an appropriate amount composition ratio and a non-aqueous emulsified composition containing an appropriate amount of glycerin are an original non-aqueous emulsified composition. The present inventors have newly found that the moisture retention performance can be improved without impairing the feeling of use and the like, and that the percutaneous absorbability of the drug can be enhanced when the preparation is administered to the skin.

That is, the present inventors carry out an emulsification operation under appropriate production conditions (temperature conditions, order of addition, stirring conditions) at room temperature with a predetermined amount of drug, oil, hydrophilic nonionic surfactant, glycerin and the like. After preparing a concentrated emulsion (conc base) consisting of microemulsions, adding a predetermined amount of water, water-soluble polyhydric alcohol, etc. to stabilize the emulsion, the moisture retention performance and temperature stability of the base The invention of a non-aqueous emulsification type composition for blending a drug excellent in stability, blendability, release characteristics and usability of the drug has been completed.

That is, the present invention
(1) (A) a lipophilic drug,
(B) 5-30% by weight of glycerin,
(C) a hydrophilic nonionic surfactant selected from the group consisting of a glycerol fatty acid ester having a polyoxyethylene of 10 mol or more, a hardened castor oil derivative having a polyoxyethylene of 40 mol or more, and a higher polyglycerol fatty acid ester,
(D) an oil selected from the group consisting of liquid paraffin, squalane, silicone oil, and
(E) Group consisting of isopropyl myristate, octyldodecyl myristate, tri-2-ethylhexyl glyceryl, crotamiton, diisopropyl adipate, ethylene glycol salicylate, propylene carbonate, dibutyl sebacate, diethyl sebacate, triacetin, ethyl oleate, isostearic acid A non-water emulsified composition comprising the oil selected from (2) The non-water emulsified type according to (1), wherein the glycerin content is 10 to 25% by weight. (3) The nonaqueous emulsion composition according to (1) or (2) , wherein the hydrophilic nonionic surfactant of (C) is a hardened castor oil derivative having 40 mol or more of polyoxyethylene. (4) The oil component of (D) is squalane.
Wherein the oil of (E), tri -2-ethylhexyl glyceryl, crotamiton, is selected from the group consisting of diisopropyl adipate, (1) a nonaqueous emulsion-type composition according to any one of - (3) (5) further A non-aqueous emulsion composition according to any one of (1) to (4), which contains a water-soluble polyhydric alcohol selected from the group consisting of diethylene glycol, polyethylene glycol, propylene glycol and 1,3-butylene glycol (6) The amount of oil (oil and higher fatty acid) is 0.5 to 35.0% by weight of the whole, and the water-soluble polyhydric alcohol (including glycerin) is 5.0 to 35.0% by weight of the whole. The ratio of the amount of oil and the hydrophilic nonionic surfactant in preparing the concentrated emulsion is in the range of 1: 1 to 1:30, and the hydrophilic nonionic surfactant and the water-soluble polyvalent alcohol The nonaqueous emulsion composition according to any one of (1) to (5) (7), wherein the lipophilic drug of (A) is in a range of 1: 5 to 1:60. The nonaqueous emulsion composition according to any one of ( 1) to (6), which is selected from steroids, vitamins, anti-inflammatory agents, antibiotics, immunomodulators, and antitumor agents.

As the hydrophilic nonionic surfactant used in the present invention, those having a relatively large hydrophilic group and hydrophobic group are preferred. In particular, in this method, since the interface film basically has a strong microemulsion structure, it is preferable that the surfactant used has a high HLB compared to the conventional emulsification system. For example, higher fatty acid esters and higher alcohol ethers having a polyoxyethylene (POE) of 20 mol or more, phytosterols and cholesteryl ethers of 15 mol or more of polyoxyethylene (POE), and glycerin fatty acid esters of 10 mol or more of polyoxyethylene (POE) Further, hardened castor oil derivatives, polyglycerin higher fatty acid esters and the like having 40 mol or more of polyoxyethylene (POE) are preferable.

However, it can also be applied to cetyl ethers and glycols having a polyoxyethylene (POE) content of 10 mol or more and a polyoxypropylene (POP) content of 4 mol or more, and are semi-solid or solid lipophilic nonions at room temperature. Surfactants, ie higher fatty acid esters of glycerin such as glyceryl monostearate, higher fatty acid esters of propylene glycol such as propylene glycol monostearate, higher fatty acid esters of pentaerythritol such as pentaerythritol monostearate, sorbidan monostearate Higher fatty acid esters of sorbidane such as rate, and higher fatty acid esters of polyglycerin such as hexaglyceryl pentastearate can also be used.

The oil phase component used in the present invention is not particularly limited as long as it is an oil that can dissolve the hydrophilic nonionic surfactant and the compounding agent, but a low polarity oil (IOB: Ionic organic Balance ≦ 0.2) And a medium to high polarity oil component (IOB ≧ 0.5) are preferred.

Examples of low polar oils include vegetable oils such as liquid paraffin, squalane, silicon oil, olive oil, jojoba oil, sesame oil, etc., and medium to high polar oils include isopropyl myristate, octyldodecyl myristate, Examples include glyceryl triisooctanoate, crotamiton, diisopropyl adipate, ethylene glycol salicylate, propylene carbonate, dibutyl sebacate, diethyl sebacate, triacetin, ethyl oleate, and isostearic acid.

In the non-aqueous emulsion composition of the present invention, the amount of oil (oil and higher fatty acid) is preferably 0.5 to 35.0% by weight based on the total amount of the final preparation. Further, the blending ratio of each component constituting the oil content is preferably 3 to 97% by weight of low polarity oil, and 1 to 25% by weight of medium to high polarity oil.

The water-soluble polyhydric alcohol used in the present invention is not particularly limited as long as it has two or more hydroxyl groups in the molecule and is generally used for external preparations and cosmetics. For example, one or two of glycerin, propylene glycol, diethylene glycol, dipropylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, polyglycerin, polyethylene glycol 300-1500, sorbitol, xylitol, mannitol, etc. It can be used in combinations of more than one species.

When higher fatty acids are used, saturated fatty acids having 14 to 22 carbon atoms, hydroxy saturated fatty acids, ethylene saturated or monoesters of hydroxy saturated fatty acids are preferred.

In the present invention, it is easier to produce a non-aqueous emulsion composition, and a concentrated emulsion (conc base) with a water-soluble polyhydric alcohol is separately diluted with purified water (hereinafter referred to as post-added water), A lower monohydric alcohol and further the water-soluble polyhydric alcohol described above can be used in combination with the post-added water. As this kind of lower monohydric alcohol, methyl alcohol, ethyl alcohol, propyl alcohol, isopropyl alcohol and the like are preferable.

The drug that can be blended in the composition of the present invention is not particularly limited as long as it is a lipophilic drug. Examples thereof include anti-inflammatory drugs, antibiotics, antibacterial drugs, immune preparations, antitumor drugs, and vitamins. It is done. More specifically, for example, in conventional emulsion preparations, various buffers are used, and steroids (cortisone, hydrocortisone, prednisolone, dexamethasone, betamethasone) that need to suppress the hydrolysis reaction by adjusting the optimum pH. Ester compounds such as parameterzone, triamcinolone, fluocinolone acetonide, etc.), female hormones (estrone, estradiol, ethinyl estradiol, diethylstilbesterol, progesterone, etc.) can also be used.

In addition, lipophilic drugs that are difficult to mix stably with ordinary emulsion preparations and could not be expected to be released from the preparation, such as vitamins (vitamin A1, vitamin A2, provitamin A and derivatives thereof, vitamins, etc. B2, vitamin B6 and its derivatives and analogs, vitamin H, vitamin C derivatives, vitamin D2, vitamin D3, vitamin K analogs, vitamin E, vitamin E derivatives, acetyl pantothenyl ethyl ether, vitamin C tetraisopalmitate, etc.) In addition to essential fatty acids such as linoleic acid and linolenic acid arachidonic acid, vitamin H and the like, resorcin, resorcin monoacetate, ubiquinones, coenzyme and the like can be mentioned.

Further, examples of the anti-inflammatory agent include acemetacin, alclofenac, aluminoprofen, ampiroxicam, ibuprofen, indomethacin, indomethacin farnesyl, etodolac, epilisol, oxaprozin, ketoprofen, zaltoprofen, diclofenac sodium, diflunisal, sulindac, thiaprofenic acid, tenoxicam, Examples include tolfenamic acid, napemetone, naproxen, piroxicam, fenbufen, flufenamic acid, flurbiprofen, fructaphenine, pranoprofen, mefenamic acid, loxoprofen sodium, emorphazone, ketophenylbutazone, bucolome, etc.

Antibiotics include, for example, Guntamycin, Dibekacin, Kanendomycin, Rividomycin, Tobramycin, Amikacin, Fradiomycin, Sisomycin, Tetracycline, Oxytetracycline, Loritetracycline, Doxycycline, Ampicillin, Piperacillin, Ticarcillin, Cephalothin, Cephalotidin, Cephalidine , Cefrosin, cefmenoxime, cefozoline, cefataxime, cefoperazone, ceftizoxime, moxolactam, thienamycin, sulfazecin, azuleonam and the like.

Examples of the immunomodulator include tacrolimus, cyclosporine, azathioprine, mizoribine, NFKB decoy and the like.

Examples of the antitumor agent include methotrexate, actinomycin D, mitomycin C, adriamycin, netocalcinostatin, cytosine arabinoside, fluorouracil, tetrahydrofuryl-5-fluorouracil, lentinan, levamisole, bestatin and the like.

The production method of the non-aqueous emulsion composition of the present invention is not particularly limited, but from an oil phase containing an oily component and a drug and an aqueous phase containing a polyhydric alcohol and a hydrophilic nonionic surfactant. The system is mixed and the oily component is refined in the aqueous phase to form a concentrated emulsion (conc base). The concentrated base is diluted with the post-added aqueous phase, and if necessary, A secondary process of thickening is suitable.

Various conditions for preparing the oil phase in the primary emulsification step of the present invention are appropriately selected. In order to uniformly mix and dissolve the oil component and the drug, the oil component is 60 to 90 ° C., preferably 65 It is desirable to mix and dissolve at -80 ° C. If the temperature is too low, it may be difficult to uniformly mix and dissolve the oil component.

Various conditions for preparing the aqueous phase in the primary emulsification step of the present invention are appropriately selected. To uniformly mix and dissolve the polyhydric alcohol and the hydrophilic nonionic surfactant, these are used. It is desirable to mix and dissolve at room temperature to 50 ° C, preferably at room temperature to 40 ° C.

Next, the preparation of the concentrated emulsion (conc base) involves gradually adding the oil phase to the aqueous phase while stirring the aqueous phase. The temperature at which the conc base is prepared is appropriately selected depending on the types of the oil phase and the aqueous phase, and is usually room temperature to 70 ° C, preferably room temperature to 50 ° C, more preferably room temperature. If the temperature is too low, emulsification may be difficult, and if it is too high, the formation of fine emulsion particles may be affected. Therefore, when the oil phase is dissolved at a high temperature, it is desirable to cool it to a predetermined temperature when it is added to the aqueous phase. However, the oil phase is in a liquid state until it gets tired, and it is a condition at the time of manufacturing the conch base. If the oil phase is solidified, it is difficult to produce.

The blending amount of the water-soluble polyhydric alcohol is preferably 0.5 to 65.0% by weight, more preferably 5 to 35% by weight. On the other hand, the smaller the amount of oil, the easier it is to prepare a non-aqueous emulsion type composition. However, when the amount is too small, the water retention ability is poor and the stickiness of water-soluble polyhydric alcohols may appear in terms of usability (feel). is there. Therefore, the blending ratio of the nonionic surfactant to the water-soluble polyhydric alcohol in the preparation of the non-aqueous emulsion composition is preferably in the range of 1: 5 to 1:60. The blending ratio of the nonionic surfactant to the oil content is preferably in the range of 1: 1 to 1:30. And the compounding ratio of an oil phase and a water phase has the preferable range of 1: 0.5-1: 4.

In general, the more the nonionic surfactant is added to the amount of oil, the easier it is to produce an emulsified composition, but this is not preferable for skin safety. On the contrary, if the amount is small, it is difficult to obtain a fine emulsion structure, and it becomes difficult to produce an emulsified composition. However, in the case of non-aqueous emulsification, in principle, a concentrated emulsion (conc base) of a water-soluble polyhydric alcohol and an oil component is used even if the amount of the nonionic surfactant is small relative to the oil content. Since the water phase is stabilized by purified water for stabilizing the water phase of the oil-in-water emulsion, that is, post-added water, a composition having excellent emulsification stability can be produced. In this case, in addition to the water-soluble polyhydric alcohol, it is useful to add sodium pyrrolidonecarboxylate or sodium cetyl sulfate or amino acids. This is because these additions are present at the emulsification interface to prevent aggregation of the emulsified droplets and improve the emulsification stability of the system. Their proportion is 0.001 to 45% by weight.

In addition, when the amount of oil and nonionic surfactant is extremely large and the blending amount of water-soluble polyhydric alcohol is relatively small (35% or less), strong mechanical stirring force (Manton Gaurin or Microfluidizer) ), There is a tendency that the emulsion droplets cannot be made fine and a stable emulsion structure cannot be obtained. In such a case, a large amount of the water-soluble polyhydric alcohol may be prescribed. In some cases, it is difficult to emulsify with glycol depending on the strength of the stirring force and how it is applied. Usually, non-aqueous emulsification can be prepared at room temperature. In such a case, a non-aqueous emulsification type composition having a strong emulsification structure can be obtained by applying a strong stirring force or temperature. .

When a drug is blended in the non-aqueous emulsion composition of the present invention, there is no particular problem as long as the drug is an oil-soluble drug that is liquid at room temperature. This is a general matter for ordinary emulsion compositions. However, when the drug is a crystal (solid), the amount of highly polar oil component for dissolving the drug cannot be increased. On the other hand, as a feature of the non-aqueous emulsion type composition, the blending amount of the highly polar oil can be blended at a relatively high dose.

Further, since it has a strong emulsification structure, temperature stability does not change even when diluted with water, lower monohydric alcohol or water-soluble polyhydric alcohol. The non-aqueous emulsion composition is characterized by having no structural viscosity, but if necessary, it can have a structural viscosity by adding a thickener such as a water-soluble polymer or a clay mineral such as bentonite. it can. Alternatively, the viscosity can be increased by adding a gel agent such as carboxyvinyl polymer to the post-added water phase. Furthermore, it is also possible to adjust appropriately to the viscosity calculated | required by increase / decrease in surfactant. However, even a low-viscosity non-water-emulsifying composition has excellent temperature stability and excellent usability, and because it is a fine emulsion particle, it is well-familiar with the skin and improves the skin permeability of the drug. Is also excellent. Further, if necessary, agents other than the above-mentioned additives from pigments, fragrances, pigments, preservatives, antioxidants and ultraviolet absorbers can be appropriately blended within the range constituting the object of the present invention. For example, creams, emulsions, essences, packs, cats, etc. can be appropriately distributed. In this emulsification step, a small amount of water can be added to the aqueous phase component in advance in addition to the hydrophilic surfactant and the water-soluble polyhydric alcohol.

According to the present invention, a drug that could not be stably blended in a conventional emulsion preparation can be stably blended in a non-aqueous emulsion composition having a microemulsion structure. Furthermore, by blending glycerin, the moisture retention is significantly improved as compared to the example blended in a normal emulsion type composition. In addition, it is possible to provide a non-aqueous emulsified composition excellent in drug release properties, that is, skin transferability.

Further, since the non-aqueous emulsion composition of the present invention is extremely stable, it can be diluted with water, lower alcohol, water-soluble polyhydric alcohol, etc. without destroying the microemulsion structure. It can be used as a novel base for skin cosmetics.

Hereinafter, the present invention will be described in more detail with reference to Examples and Test Examples, but the present invention is not limited thereto.

Table 1 shows the formulations and average particle sizes of Examples 1 to 6 and Comparative Examples of the present invention.

[Example 1]
The oil phase components in Table 1 were heated and stirred at 75 to 80 ° C. and dissolved, and then the temperature was adjusted at room temperature to prepare an oil phase. On the other hand, the aqueous phase component was heated to completely dissolve the surfactant, and then stored at room temperature. The oil phase was gradually added while stirring the aqueous phase with a 1/4 horsepower homomixer (manufactured by Tokushu Kika Kogyo Co., Ltd.). After completion of the addition, the mixture was further stirred for 90 seconds to prepare a concentrated emulsion (conc base). At room temperature, the post-added water phase component was dissolved, and the post-added water phase was added to the conc base, followed by stirring for 90 seconds to obtain a non-aqueous emulsion composition.

[Examples 2 to 6]
The same operation as in Example 1 was performed to obtain a non-aqueous emulsion type composition.

[Test Example 1] Particle size Examples 1 to 6 and Comparative Example were measured with a laser diffraction type particle size distribution measuring device (Horiba, LA-700). The average particle diameter (median diameter) results are shown in Table 1. From this, it can be seen that all the non-aqueous emulsion compositions are fine emulsions having an average particle size of 1 μm or less. For reference, the average particle size of a commercially available oil-in-water moisturizing cream containing 20% glycerin used in Test Examples was 20.06 μm.

[Test Example 2] Moisturizing Performance Test Examples 1 to 6 and Comparative Example, as a control, a commercially available cream (containing 20% glycerin) and a commercially available ointment (drug dispersed in white petrolatum base) The performance was measured at each of five locations after 0.5, 1, 2, and 5 hours using a high-frequency conductivity measuring apparatus (SKICON-200, IBS: skin stratum corneum moisture measuring apparatus) using animals. The test results are shown in FIG.

As a result, compared with the comparative example which does not mix | blend glycerol, Example 1 to Example 6 which mix | blends glycerin has increased the moisture retention performance. Even in a preparation containing 20% glycerin, the non-aqueous emulsion preparation has a higher moisture retention performance than a normal oil-in-water cream.

[Test Example 3] Pharmacological tests were carried out on the pharmacological effects of Examples 1 to 6, commercially available steroid creams and commercially available steroid ointments.
Test method: When each sample 50mg is applied to a skin sensitization test tape (Fin Chamber on Scanpole, Otsuka Pharmaceutical), affixed and fixed to an animal, and then peeled off after 2 and 4 hours The skin was measured with a color difference meter (CR-300, Minolta). FIG. 2 shows the test results of those three times (each measurement has three skins once). In addition, the standard white plate was measured at the same time. From the measurement results, the evaluation value is the difference of the skin color difference (E (a)) between the standard white board and the skin color difference before application (E (b)) and the white board after application (after 2 or 4 hours) [E (a)] -E (b)] was defined as the degree of whitening. This value indicates that the drug is absorbed as it becomes negative.

The non-aqueous emulsified composition was a result that the drug easily migrated to the skin.

From the results of the above-described moisturizing performance test and pharmacological test, the non-aqueous emulsion composition containing glycerin is a non-water emulsifying composition in which the moisturizing performance and drug transferability to the skin are not blended with glycerin, and the conventional emulsion composition It was found to be superior to products and ointments.

It is a figure which shows the result of a moisture retention performance test. It is a figure which shows the result of a pharmacological test.

Claims (7)

(A) a lipophilic drug,
(B) 5-30% by weight of glycerin,
(C) a hydrophilic nonionic surfactant selected from the group consisting of a glycerol fatty acid ester having a polyoxyethylene of 10 mol or more, a hardened castor oil derivative having a polyoxyethylene of 40 mol or more, and a higher polyglycerol fatty acid ester,
(D) an oil selected from the group consisting of liquid paraffin, squalane, silicone oil, and
(E) Group consisting of isopropyl myristate, octyldodecyl myristate, tri-2-ethylhexyl glyceryl, crotamiton, diisopropyl adipate, ethylene glycol salicylate, propylene carbonate, dibutyl sebacate, diethyl sebacate, triacetin, ethyl oleate, isostearic acid A non-aqueous emulsified composition comprising an oil component selected from the group . The non-aqueous emulsion composition according to claim 1, wherein the glycerin content is 10 to 25% by weight . The non-water emulsion composition according to claim 1 or 2 , wherein the hydrophilic nonionic surfactant (C) is a hardened castor oil derivative having 40 mol or more of polyoxyethylene . The oil component (D) is squalane.
The non-aqueous emulsion composition according to any one of claims 1 to 3, wherein the oil component (E) is selected from the group consisting of tri-2 ethylhexyl glyceryl, crotamiton, and diisopropyl adipate . Furthermore, the nonaqueous emulsion type composition of any one of Claims 1-4 containing the water-soluble polyhydric alcohol selected from the group which consists of diethylene glycol, polyethyleneglycol, propylene glycol, and 1, 3- butylene glycol. Thing . Concentrated emulsification with an oil content (oil content and higher fatty acid) of 0.5 to 35.0% by weight, and a water-soluble polyhydric alcohol (including glycerin) of 5.0 to 35.0% by weight. The ratio of the amount of oil and the hydrophilic nonionic surfactant in producing the product is in the range of 1: 1 to 1:30, and the blending ratio of the hydrophilic nonionic surfactant and the water-soluble polyhydric alcohol Is a range of 1: 5 to 1:60 , The non-aqueous emulsion type composition of any one of Claims 1-5 . The non-aqueous emulsion composition according to any one of claims 1 to 6, wherein the lipophilic drug (A) is selected from steroids, vitamins, anti-inflammatory agents, antibiotics, immunomodulators, and antitumor agents. Thing .

Images